A late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings ...
Zepbound, a popular weight loss drug from Eli Lilly, may help people with sleep apnea. Based on recent findings, Eli Lilly plans to submit the material to the U.S. Food and Drug Administration to ...
Tirzepatide, the main ingredient in the injected weight loss and diabetes drugs Zepbound and Mounjaro , might help reduce obstructive sleep apnea symptoms, preliminary results from two late-stage ...
Eli Lilly’s weight loss drug Zepbound has been shown to “significantly reduce” obstructive sleep apnea (OSA) in adults with obesity, the company said Wednesday. Injections of tirzepatide ...
Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults in two company trials, drug maker Eli Lilly announced Wednesday.
Sleep apnea events during REM sleep are linked to verbal memory impairment in older adults at risk for Alzheimer's disease.
Do you snore? Does your partner say you snore? Snoring is disruptive and, in some severe cases, even life-threatening.
Weight loss drugs like Ozempic and Mounjaro have gained great traction in recent months, and now drugmakers have found another benefit of the popular medications. Eli Lilly, the manufacturer of ...
Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said in a release Wednesday. Obstructive sleep apnea affects about 39 ...
Tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced sleep apnea symptoms for people with obesity. The drug improved sleep apnea symptoms whether or not people used a PAP machine.
Share on Pinterest A new study found people takeing the GLP-1 Zepbound had fewer symptoms of sleep apnea. River Rock Photos/Getty Images People with obesity who received the weight-loss drug ...